Epithelial mesenchymal transition (EMT) is a well conserved process by which polarized, immotile epithelial cells transition into motile mesenchymal cells. EMT plays an important role during normal biological processes such as embryogenesis and wound healing. More recently, EMT has been studied for its role in cancer progression and metastasis. Understanding the molecular mechanisms that regulate EMT are key to developing novel therapeutic interventions for cancer. Dysregulated or uncontrolled activation of the Wnt/β-catenin signaling pathway promotes tumor progression and metastasis. The Wnt/β-catenin signaling pathway is one of the signaling pathways that has been implicated in EMT. In this review, major Wnt target genes that promote EMT as well as the various antagonists and microRNAs that regulate the Wnt/β-catenin pathway to influence EMT during cancer progression will be discussed.
Introduction
Epithelial mesenchymal transition (EMT) can be described as a process by which polarized epithelial cells lose their apical-basal polarity, reorganize their cytoskeleton and undergo biochemical changes that cause cells to gain a mesenchymal cell phenotype [1] . The discovery that cells could transform from epithelial to mesenchymal phenotypes was identified by Elizabeth D. Hay using a chick primitive streak formation model [2] . However since the identified epithelial mesenchymal transformation was later determined to be a transient and reversible process, it came to be known as epithelial mesenchymal transition. EMT occurs in three distinct biological settings: (a) during implantation, embryogenesis, and organ development; (b) during tissue regeneration and organ fibrosis; and (c) during cancer progression, invasion and metastasis [3] . The relevance of EMT in cancer progression, invasion and metastasis has recently gained importance over the past several years [4] [5] . Since treatment options are limited and overall patient prognosis is poor once metastasis has occurred, it is important to understand the molecular mechanisms regulating EMT in order to develop novel therapeutic targets and treatment options for cancer.
One of the molecular pathways that plays a critical role in promoting EMT is the Wnt/β-catenin signaling pathway. This signaling pathway has been extensively studied and plays an essential role in development [6] [7] [8] . In the absence of the Wnt ligand, the destruction complex of Axin, adenomatosis polyposis coli (APC), protein phosphatase 2A (PP2A), glycogen synthase kinase 3β (GSK3β) and casein kinase 1α (CK1α) can assemble and cause phosphorylation (at Ser33, Ser37, Thr41 and Ser45) and ubiquitinmediated proteosomal degradation of cytoplasmic β-catenin ( Figure 1 ). In the presence of the Wnt ligand, the Wnt signaling pathway is activated. The Wnt ligand initiates signaling extracellularly by binding to the seventransmembrane domain Frizzled receptor and LRP5/6 (low density lipoprotein receptor-related proteins 5 or 6) co-receptor to initiate signaling ( Figure 2) . Binding of the Wnt ligand to its receptors results in Dishevelled (Dvl) mediated disruption of the Axin/APC/ GSK3β complex leading to cytoplasmic accumulation of β-catenin. β-catenin then translocates to the nucleus, where it acts as a transcriptional coactivator and causes transcription of downstream TCF (T-cell factor)/LEF (lymphoid enhancer factor) target genes [9] [10] . Under normal cell conditions, Wnt/β-catenin signaling is precisely controlled by a delicate balance of agonists and antagonists. Dysregulated activation of the Wnt signaling pathway can occur because of loss of function mutations in antagonists of the pathway, or gain of function or constitutive activation of agonists of the pathway [11] . Dysregulated activation of the Wnt signaling pathway promotes tumor development, EMT and metastasis in a variety of cancers [8, [12] [13] [14] In the absence of Wnt ligands, the destruction complex of Axin, adenomatosis polyposis coli (APC), glycogen synthase kinase 3β (GSK3β) can assemble. GSK3β then phosphorylates β-catenin at Serine 33, Serine 37, Threonine 41 and Serine 45. Phosphorylated β-catenin gets polyubiquitinated (Ub) by an E3 ubiquitin ligase containing the F-box protein β-TrCP. Polyubiquitinated β-catenin is then degraded by the 26S proteosome and the transcription of Wnt downstream target genes is repressed.
In this review, I will discuss how activation of Wnt signaling enhances EMT, how antagonists of the Wnt signaling pathway inhibit EMT, and the role of microRNAs that regulate Wnt signaling to modulate EMT.
WNT signaling and EMT
Activation of the Wnt signaling pathway increases β-catenin stability and nuclear translocation, ultimately, resulting in transcription of various downstream target genes. Some of the crucial players of EMT, including Slug, Twist, ZEB1 and Vimentin, are Wnt target genes. Slug (Snai2) belongs to the Snail family of zinc-finger transcriptional repressors (Snail and Smuc are the other two members of this family) and can transcriptionally repress the epithelial marker E-cadherin [20] . Ecadherin is essential for epithelial cell-cell [45] and activates expression of mesenchymal markers such as Vimentin, Fibronectin and MMPs [46] [47] . Snail (Snai1) is primarily regulated by protein turnover and changes in subcellular localization. Studies examining the role of S33Y β-catenin showed that E-cadherin was significantly decreased [48] . Interestingly, S33Y β-catenin also caused an increase in nuclear Snail protein in a temporal fashion. Snail itself represses E-cadherin transcription and S33Y β-catenin mediates its E-cadherin suppression via Snail. Further studies showed that S33Y β-catenin caused an increase in Axin2 levels, which chaperones GSK3β and stabilizes Snail protein to enhance EMT [48] . GSK3β phosphorylates Snail at two phosphorylation motifs. Phosphorylation at one motif results in ubiquitin-mediated proteosomal degradation of Snail. Phosphorylation at the second motif promotes nuclear export of Snail [49] . Thus like β-catenin, in the absence of Wnt signaling, Slug is phosphorylated by GSK3β and undergoes degradation. In the presence of Wnt ligands, GSK3β kinase activity is inhibited and nuclear slug levels increase allowing EMT and increased invasive abilities [16] . Thus GSK3β controls Snail protein turnover and activity. [50] .
Thus activation of Wnt signaling enhances EMT by several mechanisms, including transcriptional upregulation of key EMT players, and regulation of protein stability and subcellular localization of EMT players and β-catenin.
WNT pathway agonists and EMT
Under normal cell conditions, the Wnt signaling pathway plays a critical role in the control of cell proliferation, cell fate specification and differentiation, and is tightly regulated by several antagonists. There are at least seven known antagonists of the Wnt signaling pathway. These include the secreted Frizzled-related proteins (sFRPs), Cerberus, Crescent, Wnt inhibitory factor-1 (WIF-1), Wise, Naked cuticle homolog 1 (NKD1) and Dickkopfs (DKKs) [11] . Since activation of the Wnt signaling pathway enhances EMT, it can be expected that antagonists of the Wnt pathway would inhibit EMT.
Secreted Frizzled-related proteins and WIF-1 inhibits Wnt signaling by binding to and sequestering Wnt ligands. As would be expected, secreted Frizzled-related protein 1 (sFRP1) caused an inhibition of EMT [51] [62] . Interestingly the Wnt antagonist WIF1 causes an increase in the expression and activity of miR-200c [63] . Thus an antagonist of the Wnt signaling pathway upregulates a miRNA that suppresses EMT, further modulating EMT. miR-203 expression is downregulated in cancer cells and low levels of miR-203 expression is associated with EMT. Studies showed that miR-203 inhibits EMT by indirectly enhancing DKK1 expression and inhibiting Wnt signaling [64] . miR-29b is another miRNA that inhibits activation of Wnt target genes by downregulating coactivators of β-catenin and overexpression of miR-29b caused a reversal of EMT [65] . Similarly loss of miR-101 promotes Wnt signaling-mediated EMT. Using both the degradation resistant β-catenin and a dominant negative TCF-4, there was a strong association between activated Wnt signaling and miR-101 repression [66] .
Other microRNAs work in concert with the Wnt signaling pathway to enhance EMT. miR-374a is upregulated in primary tumors from patients with distant metastases. miR-374a can directly target several antagonists of the Wnt pathway including WIF1, PTEN and Wnt5A thereby activating Wnt signaling. miR-374a thus promotes EMT by activating Wnt signaling [67] . miR-181 is also directly induced when Wnt signaling is activated. The promoters of miR181a and miR-181b both have β-catenin/TCF-4 binding sites, which upregulate miRNA expression following activation of Wnt signaling [68] . miR-181a has further been identified to induce EMT [69] . Additionally, miR-181a was also shown to target WIF1, an antagonist of Wnt signaling [70] . Thus by targeting antagonists of the Wnt signaling pathway, miR-181a further enhances Wnt signaling and EMT.
Thus miRNA that modulate Wnt signaling also regulate EMT by targeting the activation of Wnt signaling, by upregulating Wnt signaling directly and/or by targeting Wnt antagonists.
Conclusions
The Wnt signaling pathway is an important regulator of tumor progression and metastasis. The finding that Wnt signaling also modulates EMT, an essential step in tumor progression, invasion and metastasis, makes this pathway an attractive target for developing novel therapeutic interventions. US Food and Drug Administration (FDA)-approved drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the COX2 inhibitor celecoxib were shown to inhibit Wnt signaling in several cancers [71] [72] [73] [74] .
Small molecules such as pyrvinium, blocking antibodies such as Wnt3A-neutralizing antibodies, and peptides such as Fzd7 extracellular domain peptides have all been assessed to target Wnt signaling in cancer [75] . Thus while several therapies have already been developed to target Wnt signaling [75] [76] [77] , with increasing information about novel regulation mechanisms of Wnt signaling, we will be able to fine tune currently available therapies for developing better, next-generation therapeutics.
As shown schematically in Figure 3 , we can appreciate that the Wnt signaling pathway regulates EMT by multiple intricately connected mechanisms. Several of the downstream target genes of the Wnt signaling pathway are critical mediators of EMT. Further, signaling activated in the presence of Wnt ligands also regulates the protein stability and subcellular localization of EMT mediators. More recent studies have revealed that miRNAs can also regulate EMT via the Wnt signaling pathway. By directly targeting β-catenin, miRNAs can inhibit Wnt-mediated EMT. Additionally, by targeting antagonist of the Wnt signaling pathway, miRNAs can promote EMT. As research in the field continues, we might find other novel molecules/miRNAs that also regulate Wnt signaling. As new molecules and signaling mechanisms that regulate Wnt signaling are uncovered, we will have novel therapeutic targets/therapies for the treatment of cancer. coreceptor to initiate signaling. This activates Dishevelled (Dvl) which causes disruption of the destruction complex of Axin, APC and GSK3β (which in the absence of Wnt ligands, causes degradation of β-catenin). β-catenin accumulates in the cytoplasm, translocates to the nucleus and along with TCF (T-cell factor) causes transcription of downstream target genes. Several of these downstream target genes (Slug, Twist, Zeb1, Vimentin, Fibronectin and MMPs) are key regulators of EMT. Some of the Wnt downstream target genes, including Slug, Twist and Zeb1, are transcriptional repressors of E-cadherin. E-cadherin binds to and sequesters β-catenin at cell-cell junctions. However when E-cadherin is repressed, β-catenin is released into the cytoplasm and can translocate to the nucleus and can, in turn, activate Wnt signaling. Activation of Wnt signaling also modulates both protein stability and subcellular localization of Snail and Slug, key regulators of EMT. Activation of Wnt signaling and EMT can be inhibited by the Wnt pathway antagonists -DKK1, sFRPs and WIF1. 
